Family Motivational Intervention in Schizophrenia (FMI)

Motivational Interviewing and Interaction Skills Training for Carers to Change Cannabis Use in Young Adults With Recent-onset Schizophrenia: Randomised Controlled Trial

Cannabis use by people with schizophrenia is associated with family distress and poor clinical outcomes. Therefore, an Family Motivational Intervention (FMI) was developed to help parents to motivate their child with a diagnoses of recent-onset schizophrenia to reduce cannabis use.

In a single-blind randomised clinical trail with 75 patients with the diagnosis of schizophrenia, parents will be assigned to either FMI or to routine care. Assessments will be conducted at baseline and at a 10- and 22-month follow-up. The study hypothesis is that FMI will be more effective than routine care in reducing (a) cannabis use in patients and (b) distress and sense of burden in parents.

Study Overview

Status

Unknown

Conditions

Study Type

Interventional

Enrollment (Actual)

147

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Holland
      • Amsterdam, North Holland, Netherlands, 1066 DP
        • Academic Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 40 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Clinical diagnosis of schizophrenia or psychotic-related disorder
  • Onset of schizophrenia or related disorder within pervious the 10 years
  • Cannabis use at least 2 days per week in the 3 months prior to the assessment
  • Antipsychotic medication in prescribed or indicated
  • At least 10 hours of contact with the parents each week in the last month

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Family Motivational Intervention
An intervention provided to parents consisting of 6 sessions of training in Interactions Skills and 6 sessions training in Motivational Interviewing.
A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
Active Comparator: Routine care for parents
Routine care for parents consisting of 2 sessions psycho-education and individual support
A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Cannabis use in patients with a diagnosis of recent-onset schizophrenia
Time Frame: Baseline (before the start of the intervention)
Baseline (before the start of the intervention)
Cannabis use in patients with a diagnosis of recent-onset schizophrenia
Time Frame: 10-month follow-up (3 months after the intervention has ended)
10-month follow-up (3 months after the intervention has ended)
Cannabis use in patients with a diagnosis of recent-onset schizophrenia
Time Frame: 22-month follow-up (15 months after the intervention has ended)
22-month follow-up (15 months after the intervention has ended)

Secondary Outcome Measures

Outcome Measure
Time Frame
Medication adherence in patients with a diagnosis of recent-onset schizophrenia
Time Frame: Baseline (before the start of the intervention)
Baseline (before the start of the intervention)
Medication adherence in patients with a diagnosis of recent-onset schizophrenia
Time Frame: 10-month follow-up (3 months after the intervention has ended)
10-month follow-up (3 months after the intervention has ended)
Medication adherence in patients with a diagnosis of recent-onset schizophrenia
Time Frame: 22-month follow-up (15 months after the intervention has ended)
22-month follow-up (15 months after the intervention has ended)
Quality of life in patients with recent-onset schizophrenia
Time Frame: Baseline (before the start of the intervention)
Baseline (before the start of the intervention)
Quality of life in patients with recent-onset schizophrenia
Time Frame: 10-month follow-up (3 months after the intervention has ended)
10-month follow-up (3 months after the intervention has ended)
Quality of life in patients with recent-onset schizophrenia
Time Frame: 22-month follow-up (15 months after the intervention has ended)
22-month follow-up (15 months after the intervention has ended)
Stress in parents due to caring for a child with recent-onset schizophrenia
Time Frame: Baseline (before the start of the intervention)
Baseline (before the start of the intervention)
Stress in parents due to caring for a child with recent-onset schizophrenia
Time Frame: 10-month follow-up (3 months after the intervention has ended)
10-month follow-up (3 months after the intervention has ended)
Stress in parents due to caring for a child with recent-onset schizophrenia
Time Frame: 22-month follow-up (15 months after the intervention has ended)
22-month follow-up (15 months after the intervention has ended)
Expressed emotion in parents of patients with recent-onset schizophrenia
Time Frame: Baseline (before the start of the intervention)
Baseline (before the start of the intervention)
Expressed emotion in parents of patients with recent-onset schizophrenia
Time Frame: 10-month follow-up (3 months after the intervention has ended)
10-month follow-up (3 months after the intervention has ended)
Expressed emotion in parents of patients with recent-onset schizophrenia
Time Frame: 22-month follow-up (15 months after the intervention has ended)
22-month follow-up (15 months after the intervention has ended)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Gerard Schippers, Prof. dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • Principal Investigator: Don Linszen, Prof.dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • Study Chair: Lieuwe de Haan, Dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2006

Primary Completion (Anticipated)

August 1, 2010

Study Completion (Anticipated)

February 1, 2011

Study Registration Dates

First Submitted

July 20, 2010

First Submitted That Met QC Criteria

July 21, 2010

First Posted (Estimate)

July 22, 2010

Study Record Updates

Last Update Posted (Estimate)

July 22, 2010

Last Update Submitted That Met QC Criteria

July 21, 2010

Last Verified

February 1, 2008

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on Family Motivational Intervention

3
Subscribe